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Background: The number of cesarean scar pregnancy (CSP) has significantly increased in the recent decade.
Although uterine artery embolization (UAE) has been adopted to minimize the blood loss during uterine curettage
removing of CSP, massive bleeding and uterine rupture can still be frequently encountered. The aim of this study
was to compare the efficacy and safety of a novel combined laparoscopy and hysteroscopy technique with the
traditional curettage in removing the conceptus and repairing the incision defect following the UAE management
of CSP.
Methods: The CSP patients (n = 58) diagnosed between March 1, 2005 and March 1, 2010 were enrolled in three
medical centers in Shanghai, China. All of these patients have undergone intra-arterial methotrexate, UAE and one
of the following treatments: combined laparoscopy and hysteroscopy (study group, n = 25) and uterine curettage
(control group, n = 33). Their medical records and 2-year outcomes were reviewed. The CSP removal rate, amount
of blood loss during the treatment, incision repair rate (note: the post-curettage healing process of the incision
defect was seen as a form of natural incision repairing, i.e., the self-repair mode), hospital stay, β-hCG regression
time and postoperative sequelae were compared between two groups.
Results: The CSP removal rate in the study group (100%) was significantly higher than that (79%) in the control
group (p = 0.024). The average blood loss was 78.0 mL in the study group, which was much less than the 258.5 mL
(p = 0.004) in the control group. A satisfactory incision repair rate (96%) was achieved in the study group, while
it was 25% (p < 0.001) in the control group. Moreover, the study group had significantly shorter hospital stays
(p = 0.043) and β-hCG regression times (p = 0.033), lower rates of postoperative abdominal pain (p = 0.035) and
menstruation abnormalities (p = 0.043).
Conclusions: Combined laparoscopy and hysteroscopy is much safer and more effective than uterine curettage as
a supplementary measure to remove the conceptus and repair the cesarean incision following the UAE
management of CSP.
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Caesarean scar pregnancy (CSP) is a rare type of ectopic
pregnancy, which is caused by the implantation of the em-
bryo within the prior delivery section scar [1]. Because the
ectopic embryo at the scar site has extremely limited room
for growth and the surrounding blood supply is relatively
abundant, the clinical status of CSP is highly unstable and
can progress rapidly [1]. Mothers with CSP are confronted
with risks of unpredictable massive bleeding or more fatal
complications, such as hemorrhagic shock and uterine
rupture [1]. Although the incidence of CSP is rather low,
numbering no more than 1/1,000 pregnancies, the abso-
lute number of women suffering from this disorder has
increased greatly in the past decade [1]. Especially in
mainland China, CSP is no longer a rare event in clinics
(increased from 7.8 cases/100,000 outpatient · years in
2000 to 36.2 cases/100,000 outpatient · years in 2010 in
our institutes; data not published), which may be due to
the increase of the caesarean section rate (more than 50%
of all births [2]). Systemic or local administration of
methotrexate (MTX) and/or uterine artery embolization
(UAE) followed by uterine curettage to remove the con-
ceptus has been suggested as standard treatment for CSP
[3-6]. The primary purpose of MTX and/or UAE is to
minimize blood loss during the curettage. However, these
treatments do not eliminate the risk of massive bleeding
or uterine perforation thereafter. According to other
reports and our own experience, massive bleeding and
penetrating injury to the uterus may still be encountered
by clinicians who perform curettage after UAE [5,6].
In addition, postoperative sequelae, such as abnormal
uterine bleeding and dull abdominal pain, can often
occur and be attributed to the unrepaired tissue defect at
the scar site [7,8].
The tissue defect, such as the sub-endometrial micro-
tubular tract, remaining at the incision site of the uterus
isthmus is the major cause of CSP [1,9,10]. In recent
years, we have attempted to use a minimally invasive
laparoscopy and hysteroscopy combination surgery fol-
lowing MTX and UAE to repair this local tissue defect,
as well as to remove the ectopic conceptus from CSP pa-
tients safely. The present study was designed to compare
the safety and efficacy of this novel therapeutic strategy
with the conventional strategy (i.e., MTX +UAE + curet-
tage) between two patient cohorts with similar clinical
characteristics. The obtained data has shown both the
short- and long-term effects of this novel strategy.
Methods
Patients
The CSP patients, who were diagnosed between March
1, 2005 and March 1, 2010 at First Maternity and Infant
Health Hospital, Tongji University; Obstetrics and Gynecology
Hospital, Fudan University and Ren Ji Hospital, Schoolof Medicine, Shanghai Jiao Tong University; Shanghai,
China, comprised the patient pool of this study. The re-
search protocol was approved by the ethics committee of
the three hospitals above. The inclusion criteria were (i)
history of previous cesarean delivery before hospitalization,
(ii) first-visit ultrasonography revealing an empty uterine
and cervical canal and a myometrial defect at the caesar-
ean scar site that was surrounded by a rich blood supply
and in which a gestational sac was embedded and (iii) be-
ing immediately treated with intra-arterial MTX +UAE
and followed by combined laparoscopy and hysteroscopy
or curettage. The exclusion criteria were (i) receiving
MTX treatment or curettage before hospitalization and/or
presenting a massive uterine hemorrhage and (ii) being
treated with conservative or other surgical measures, eg.
intramuscular MTX, curettage, hysteroscopy, etc., as the
first-line therapeutic methods. A total of 58 patients were
therefore included and then divided into two cohorts
(groups), i.e., 25 patients in the study group, who received
intra-arterial MTX+UAE + combined laparoscopy and
hysteroscopy, and 33 patients in the control group, who
received intra-arterial MTX +UAE + ultrasound-guided
curettage. The medical records and follow-up information
of these patients were carefully and thoroughly reviewed.
Treatment
The initial treatment for patients in both groups was the
same; the right femoral artery was punctured, and 5.0-F
Cobra catheters (Cordis, Brentford, Middlesex, UK) were
inserted into the bilateral uterine arteries under angio-
graphic guidance. A dose of MTX (50 mg/kg, Hengrui,
Lianyungang, Jiangsu, China) was injected into each cath-
eter, and blood flow was blocked by gelatin sponge
microbeads of two sizes: 500–700 μm and 700–900 μm
(Alicon, Hangzhou, Zhejiang, China). Patients were given
one of the following treatments: curettage or combined
laparoscopy and hysteroscopy. Both procedures were con-
ducted by a same group of clinicians within 48 hours after
UAE (we noted the hemostatic effect of UAE reached the
maximum within 48 hours and declined thereafter in our
previous clinical practice; data not published). (i) Uterine
curettage: The internal cervical os was dilated; the concep-
tus was detached with a curette under ultrasound guid-
ance and carefully pulled to the cervical canal, and then it
was dragged out of the external cervical os with a vascular
clamp. The curettage was terminated if the intraoperative
bleeding reached 200–400 mL, and this condition was
treated accordingly (e.g., vaginal gauze, uterine tampon-
ade, intravenous injection of aminomethylbenzoic acid or
reptilase). If conservative treatments failed and/or the cu-
mulative bleeding reached 800 mL, wedge resection or
hysterectomy was adopted. Laparotomy was immediately
performed in cases of uterine perforation, and the uterus
was either repaired or removed according to the severity
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scopic surgery: Laparoscopy was used for intraoperative
surveillance and intra-peritoneal surgery. The vesico-
uterine excavation was exposed by laparoscopy to visualize
the uterine isthmus. Hysteroscopy was used to determine
the exact location of the ectopic conceptus and to esti-
mate the minimal distance from it to the uterine serosa.
The conceptus was removed with a diathermy loop using
the coagulating resection and tearing maneuver under the
direct visualization of hysteroscopy. The local tissue weak-
ness or defect was further evaluated based on the degree
of translucency of the isthmus wall to hysteroscopic light.
The defect was closed using 1–0 absorbable suture under
laparoscopy (using an interrupted suturing method; gener-
ally, 1–3 stitches could be enough to close the defect). The
quality of the tissue repair was evaluated by hysteroscopy.
Patients in both groups received 3-day postoperative anti-
biotics, and the volume of vaginal bleeding and the severity
of abdominal pain (mild: bearable without any sedatives;
moderate: bearable with a common dose of paracetamol;
severe: unbearable and requiring pethidine) were recorded.
The serum β-hCG level was monitored every other day.
Patients with <10 mL of daily vaginal bleeding (determined
by weighting the sanitary napkins used every day) and a
decrease in serum β-hCG over two consecutive tests were
discharged. The main operative outcomes were divided
into two types: success and failure. A successful treatment
was defined as a complete/partial removal of the ectopic
conceptus, cease of the abnormal vaginal bleeding and
preservation of the uterus. A treatment failure was defined
as one of the following conditions: ongoing growth of the
ectopic conceptus, continuous vaginal bleeding and loss of
the uterus.
Follow-up
All patients had been followed up on a regular basis for
two years. The initial follow-up schedule was once per
week from the first day after discharge. This schedule
was adjusted to once every three months if the serum
β-hCG level returned to normal as demonstrated by two
consecutive β-hCG tests. The follow-up items that were
assessed included abdominal pain, vaginal bleeding, men-
strual status and serum β-hCG level, as well as the uterine
ultrasonography. All patients were advised to use contra-
ception for at least one year. Information regarding repeat
CSP and placenta implantation of the patients who be-
came pregnant during the follow-up period was obtained
by medical record review.
Statistical analysis
The differences in categorical data between the two groups
were compared using the two-sided χ2 test or Fisher’s exact
test, as appropriate. A two-sided Student’s t test was used
to compare the differences in the β-hCG level, the size ofthe gestational sac and the depth of implantation between
the control patients with massive bleeding (>800 mL) and
the remaining patients in the control group. SPSS 12.0
software (IBM, Armonk, New York, USA) was used, and
p < 0.05 was considered statistically significant.
Results
Demographics and clinical characteristics
The demographic and clinical characteristics of the pa-
tients in the study and control groups have been listed in
Table 1; there were no significant differences found be-
tween the two groups.
Intraoperative bleeding, complications and hospital stay
The bilateral UAE were successfully performed in all the
patients. In the study group, for the majority of the patients,
laparoscopy observed an isthmus with normal appearance.
Under hysteroscopy, a conceptus with a diameter of
1–6 cm (including the gestational sac, placenta, and vil-
lus), which protruded toward the uterine cavity, was found
at the incision in 14 patients. In eight patients, an in-
dentation, which contained placenta- or villous-like tissue
(1–2 cm in diameter), was observed. In the remaining
three patients, a conceptus (placenta, villus) with a diam-
eter of 2–4 cm, which partially protruded into the internal
cervical os and/or obstructed the cervical canal, was ob-
served. No complications occurred during the surgeries,
and the average volume of blood loss was 78.0 mL (range:
20–200 mL, Table 2). For all patients, the final hystero-
scopic examination revealed a good incision repair.
In the control group, the conceptus was successfully
removed by a single curettage in 26 patients. The aver-
age volume of intraoperative bleeding in this group was
258.5 mL (range: 20–1600 mL, Table 2). Seven patients
underwent multiple curettages because the blood loss dur-
ing the first curettage reached or exceeded 400 mL. Their
average blood loss was 507.5 mL (range: 200–680 mL).
Of them, one patient exhibited excessive intraopera-
tive bleeding (>800 mL), which was ceased conserva-
tively (e.g., uterine tamponade, hemostatic drugs) in
72 hours. This patient was transfused with 400 mL of
blood, and her total blood loss was 1200 mL. Another pa-
tient exhibited persistent vaginal bleeding (100–200 mL/
day, which increased over time) with severe abdominal
pain for two days following the curettage. After all conser-
vative methods failed, an exploratory laparotomy was
performed and revealed a perforation at the uterine isth-
mus. Due to the severely damaged tissue, the attempt to
repair the perforation was unsuccessful, and a hysterec-
tomy was performed. The total blood loss of this patient
was 1600 mL, and the volume of blood transfused was
800 mL. The preoperative serum β-hCG levels of these
two patients were 8,200 IU/L and 32,000 IU/L, respect-
ively, which had no significant difference from that of the
Table 1 Comparison of the demographic and clinical







≤30 5 (20) 7 (21.2)
31-40 16 (64) 21 (63.6)
>40 4 (16) 5 (15.2)
Gravidity (times) 0.451
≤3 17 (68) 17 (51.5)
4-6 7 (28) 14 (42.4)
>6 1 (4) 2 (6.1)
Parity (times) 0.841
1 24 (96) 32 (97)
2 1 (4) 1 (3)
Previous cesarean sections (times) 0.841
1 24 (96) 32 (97)
2 1 (4) 1 (3)
Years since the last cesarean section 0.170
≤2 3 (12) 8 (24.2)
3-5 16 (64) 13 (39.4)
>5 6 (24) 12 (36.4)
Symptoms 0.316
Menolipsis only 17 (68) 17 (51.5)
Menolipsis + vaginal
bleeding
4 (16) 10 (30.3)
Menolipsis + abdominal
pain
1 (4) 0 (0)
Menolipsis + vaginal
bleeding + abdominal pain
3 (12) 6 (18.2)
β-hCG level at hospitalization (IU/L) 0.543
≤10,000 15 (60) 15 (45.5)
10,001-30000 7 (28) 13 (39.4)
>30,000 3 (12) 5 (15.2)
Diameter of the gestational sac (cm) 0.899
≤1 2 (8) 3 (9.1)
2-3 14 (56) 20 (60.6)
>3 9 (36) 10 (30.3)
Minimal distance between conceptus
and uterine serosa (cm)
0.278
≤0.5 5 (20) 4 (12.1)
0.6-1 6 (24) 4 (12.1)
>1 14 (56) 25 (75.8)
*Data are presented as number (%).
**Two-sided χ2 test.
Table 2 Comparison of the intraoperative bleeding,
intraoperative complications, and main outcomes






Main operative outcomes 0.380
Success 25 (100) 32 (97)
Failure 0 (0) 1 (3)
One-time success rate# 0.024
Success after single
surgery
25 (100) 26 (78.8)
Success after multiple
surgeries
0 (0) 7 (21.2)##
Intraoperative bleeding (mL) 0.004
≤200 24 (96) 19 (57.6)
201-400 1 (4) 9 (27.3)
>400 0 (0) 5 (15.2)
Preservation of fertility 0.380
Uterus intact 25 (100) 32 (97)
Hysterectomy 0 (0) 1 (3)
Operation time (min.) 0.354
≤60 24 (96) 32 (97)
61-120 1 (4) 0 (0)
>120 0 (0) 1 (3)
Hospital stay (days) 0.043
≤5 9 (36) 6 (18.2)
5-10 16 (64) 21 (63.6)
>10 0 (0) 6 (18.2)
*Data are presented as number (%).
**Two-sided χ2 test.
#The one-time success rate of the combined laparoscopic and hysteroscopic
surgery or curettage after UAE.
##Two patients underwent massive uterine bleeding, of whom one
received hysterectomy.
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test) of this group. Additionally, no significant differences
in the size of the gestational sac (12 mm and 57 mm for
the two patients, respectively) or the implantation depth(distances to the serosa were 0.7 mm and 0.5 mm for the
two patients, respectively) were observed between these
two patients and the other patients (for gestational sac
size, t = −0.831, p = 0.409; for implantation depth, t =
1.551, p = 0.127; two-sided Student’s t test).
The average surgical time was 48 minutes (range: 35–
62 minutes) in the study group and 34.6 minutes (range:
15–130 minutes) in the control group, and no significant
difference was found (Table 2). The average hospital stay
was 6.5 days (range: 5–9 days) in the study group and
8.7 days (range: 5–22 days) in the control group, and
this difference was statistically significant (Table 2).
Postoperative vaginal bleeding, abdominal pain,
resumption of menstruation, serum β-hCG level and
uterine ultrasonography
During the first three postoperative days, the daily vol-
ume of vaginal bleeding among patients in the study
Table 3 Comparison of the short-term symptoms and






Duration of postoperative vaginal bleeding (days) 0.039
≤3 9 (36) 5 (15.2)
4-7 9 (36) 8 (24.2)
8-14 7 (28) 20 (60.6)
Maximal postoperative vaginal bleeding (mL/day) 0.008
≤30 23 (92) 18 (54.5)
31-50 2 (8) 13 (39.4)
>50 0 (0) 2 (6.1)
Time for serum β-hCG to return to normal (days) 0.033
≤20 19 (76) 13 (39.4)
21-30 5 (20) 12 (36.4)
31-40 1 (4) 5 (15.2)
41-50 0 (0) 3 (9.1)
Duration of postoperative abdominal pain (days) 0.572
≤3 23 (92) 32 (97)
4-7 2 (8) 1 (3)
Postoperative chronic pain 0.035




1 (4) 8 (24.2)
Duration of residual conceptus tissue at the scar site (months)# 0.163
≤1 23 (92) 25 (78.1)
2-12 2 (8) 7 (21.9)
>12 0 (0) 0 (0)
Caesarean scar condition (under ultrasonography)# <0.001
Totally healed 24 (96) 8 (25.0)
With partial dehiscence
or tissue indentation
1 (4) 22 (68.8)
With full-layer dehiscence
or diverticulum formation
0 (0) 2 (6.2)
Postoperative menstruation# 0.043
Returned to normal 23 (92) 20 (62.5)
Reduced menstrual flow 1 (4) 7 (21.9)
Increased or dripping
menses
1 (4) 5 (15.6)
*Data are presented as number (%).
**Two-sided χ2 test.
#The patient number was 32 in the control group due to one case
of hysterectomy.
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range: 0–50 mL/day). However, among patients in the
control group it was 10–120 mL (average: 28.1 mL/day).
Both the volume and duration of vaginal bleeding were
significantly lower in the study group than in the control
group (Table 3).
Mild to moderate abdominal pains were reported by
all patients. The average duration of postoperative pain
was similar between the two groups (Table 3). During
the follow-up period, one patient in the study group and
eight patients in the control group reported a recurrent
dull and/or occasionally intensified pain. The difference
in the rate of occurrence of such chronic pain was sig-
nificant between the groups (Table 3).
Patients in both groups (except one case of hysterec-
tomy) resumed menstruation within one month of surgery
(Table 3). However, more patients in the control group re-
ported irregular (reduced or increased) menstrual flows,
elongated menstrual periods or abnormal inter-menstrual
bleeding than those in the study group (Table 3).
The average serum β-hCG regression time was signifi-
cantly shorter in the study group (19.6 days, range: 15–23
days) than in the control group (29.3 days, range: 17–46
days, Table 3).
A postoperative ultrasonographic evaluation was per-
formed for all patients one month after the surgery.
High-density light spots, which suggest the existence of
a residual conceptus, were found in two patients in the
study group and seven patients in the control group
(Table 3). Expectant management was recommended to
eight patients because their β-hCG levels were normal,
and no signs of bleeding were found. For one patient in
the control group, whose serum β-hCG level was ele-
vated, a course of intramuscular injections of 50 mg
MTX (first day) and 5 mg folic acid (second day) were
applied for four cycles. Her serum β-hCG level declined
to normal after one month, but at that time a small mass
of conceptus could still be detected by ultrasonography.
The two-year follow-up, ultrasonography and pregnancy
outcomes
Regular uterine ultrasonography was performed for each
patient. All of the residual conceptuses disappeared by
the end of the follow-up. However, unhealed incision de-
fects were observed in a few patients in both groups.
Specifically, in one patient from the study group, a small
submucosal dehiscence (2 × 7 × 10 mm3) was found. In
two patients from the control group, tissue fissures (or
diverticula), which reached the uterine serosa, were de-
tected. Additionally, incision dehiscence or indentations
at different degrees were found in 22 patients from the
control group. Compared to the study group, the rate of
incision defects was significantly higher in the control
group (Table 3).After CSP, few patients wanted to become pregnant
again. Only one patient in the study group desired preg-
nancy. However, this patient ultimately failed to con-
ceive. Three patients from the study group and two
from the control group reported induced abortion due
to unplanned pregnancies. Their treatments all went
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(Table 3).
Discussion
The present study has, for the first time, comprehen-
sively compared the efficacies of combined laparoscopy
and hysteroscopy and uterine curettage as supplemen-
tary measures after UAE in the management of CSP.
Our findings demonstrate that the former technique can
be the superior choice. Since 1998, we have accumulated
more than ten years of clinical experience in treating CSP.
Worldwide, the strategies for CSP treatment have been
continuously renewed [11]. More than a dozen treatment
methods have been established, including the systemic
MTX combined with curettage, intra-gestational injection
of MTX, the transvaginal removal of the CSP, the laparo-
scopic removal of the CSP, and the hysteroscopy-assisted
evacuation of the CSP [12-19]. These techniques were all
developed to supplant the old techniques, though they
have their own drawbacks, including prolonged hospital
stay and extended duration of β-hCG recovery (e.g., sys-
temic or intra-gestational injection of MTX [12,13]), high
risk of massive bleeding and loss of the uterus (e.g., uter-
ine curettage after systemic MTX [16,17]) and high risk of
collateral injuries to adjacent organs (e.g., transvaginal re-
moval of the CSP [18,19]). Our experience indicates that a
better treatment for CSP is the one that offers a shorter
hospital stay, lower risk of severe complications, a safer
surgical process, better recovery of the function of the
uterus, and fewer postoperative sequelae. This study
showed that the strategy of intra-arterial MTX +UAE +
combined laparoscopy and hysteroscopy could satisfy
these criteria. Especially for patients with active vaginal
bleeding, this strategy can avoid the adverse outcomes a
non-hemostasis-oriented (e.g., MTX administration) or a
non-visual technique (e.g., curettage) could encounter.
Massive bleeding and uterine rupture are two severe
complications of CSP [1,12-19]. Before the introduction
of UAE, the risk of uncontrollable bleeding threatened
every clinician who performed curettage and/or adminis-
trated MTX [16,20]. The incidence of massive intraoper-
ative bleeding has reached 32%-73% [5,6,12]. Because
only a few rigid and brittle muscle fibers exist within the
scar [1,21-24], it could be very difficult to cease the
massive bleeding by traditional medical measures with-
out UAE, even under hysteroscopy [19,25-28]. Deans
et al. have reported the use of hysteroscopy to treat six
CSP patients without blocking the blood supply. As a re-
sult, one patient developed active uterine bleeding, to
whom the local hemostasis was ineffective, and ergomet-
rine and a Foley catheter tamponade were used [19]. On
the other hand, because the scar tissue is extremely weak
and the conceptus is very close to the uterine serosa
(usually <1 mm) [25], uterine perforation or rupture canoften occur as tissue necrosis emerges (e.g., after MTX
treatment) or after improper surgery [19]. For instance,
Dean et al. reported the occurrence of hematuria in a
CSP patient after an operative hysteroscopy, suggesting
the occurrence of a penetrating injury [19].
The adoption of UAE represented a technical advance-
ment, but limitations remain. One limitation is that the
independent cure rate of this technique is rather low.
Among CSP patients treated with UEA, 63%-73% re-
quire curettage to resolve vaginal bleeding or to remove
the unresorbable conceptus [4-6]. Another limitation is
that the scar tissue can be extremely fragile after UAE,
especially after co-administration of MTX [6]. Although
a single dose intra-arterial infusion process can enhance
the local concentration of MTX, the following necrosis
of the peri-conceptus tissue and the detachment of the
gestational sac can weaken the fastness of the uterine wall.
The reported rate of penetrating injures or massive bleed-
ing during curettage following intra-arterial MTX+UAE
or UAE alone has been 8%-17% [4-6,29]. In our study,
15% (5/33) of patients in the control group experienced
intraoperative bleeding of >400 mL, among whom 40%
(2/5) received a blood transfusion and 20% (1/5) required
emergency hysterectomy. In contrast, under guided lapar-
oscopy, a meticulous hysteroscopy can be performed, which
could significantly reduce the rates of intra- and postoper-
ative massive bleeding, uterine perforation and rupture, as
was demonstrated by our cohort analysis (no cases,
Table 2). Previously, Yang et al. have indicated that the risk
of massive bleeding could be increased by 17 times in pa-
tients with preoperative serum β-hCG of >50,000 IU/L
during the curettage [6]. Considering that β-hCG is
mainly secreted by the villi and decidua, the theory of
Yang et al. can be interpreted into that the implantation
depth of the embryo (or the mature degree of villi and pla-
centa) can determine the amount of intraoperative bleed-
ing. However, in our study, the preoperative β-hCG levels
of the two patients who experienced massive bleeding
(>800 mL) during the curettage were both <50,000 IU/L,
and there were no significant differences in the size or im-
plantation depth of the gestational sac between these two
patients and the other 31 patients in the control group.
Therefore, it is highly possible that other factors influ-
enced the volume of blood loss, and these factors might
be related to the number of re-opened collateral circula-
tions after UAE, the degree of angiogenesis around
the scar site or the deformity and irregular expansion
of the newly formed arteriolae [30]. Given this large
number of potential factors, it is rather difficult for a
clinician to predict the severity of intraoperative bleeding
prior to surgery. Therefore, as a highly controllable tech-
nique, the superiority of combined laparoscopy and
hysteroscopy can be significant, as was validated by our
present study.
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its superiority in reducing the postoperative sequelae in
CSP patients (Table 3). Compared with the 22% (7/32)
of control patients who had remaining conceptus tissues
after the curettage, the residual rate of only 8% (2/25)
among the study group is much better. The possible rea-
sons for the high residual rate following curettage are as
follows. (i) The intraoperative ultrasonography cannot
detect tiny (i.e., 1–5 mm) conceptus tissues, which can
continue growing or can be wrapped in blood clots, or-
ganized and enlarged several weeks later. (ii) The con-
ceptus tissues can be flattened during the curettage, but
after that, they can return to their original shapes. (iii)
For a few patients, due to a tight connection with the
uterus, part of the conceptus can be purposefully left to
prevent massive bleeding. Unlike curettage, under direct
visualization, combined laparoscopy and hysteroscopy
can thoroughly remove the conceptus. This ability has
also been reflected in the reduced postoperative bleeding
and a more rapid regression of serum β-hCG (Table 3).
In addition, patients in the study group experienced other
benefits from this new technique, including (i) a lower rate
of chronic postoperative abdominal pain or secondary
dysmenorrhea, (ii) fewer occurrences of reduced or drip-
ping menses and (iii) better tissue healing at the incision
site. These results can be explained by the different na-
tures of the two techniques. (i) The lesion range of curet-
tage is much larger than that of hysteroscopy, which can
lead to extensive adhesions of the uterine cavity, thus lead-
ing to a reduced menstrual flow. (ii) The tissue defect at
the incision site can rarely be self-healed without a medical
repair. It could be made worse by the curettage, whereby
the menstrual blood could deposit and cause dull pain and
dripping menses. Moreover, if endometrial cells implant
into the myometrium via the defect, leading to adenomyo-
sis, secondary dysmenorrhea may occur.
This study has some limitations. One limitation is that,
as a retrospective study, the patients were not randomly
allocated to the treatment arms which might have caused
biases, such as the clinical observation bias occurred be-
tween medical centers and the technical selection bias for
patients with different disease severities. The second limi-
tation is that the influences of the two strategies on the fu-
ture pregnancy outcomes cannot be properly compared
because the desire to conceive was notably low in both
groups. Thirdly, we also cannot evaluate the effect of
the treatment cost on patient’s choice, as the medical
record did not show any information on the treatment
expense of each patient. Nevertheless, considering that
the additional cost of combined laparoscopy and hys-
teroscopy over curettage is approximately 1,000 USD,
which can be afforded by most of our patients, we
believe this strategy may be a preferential choice in future
gynecological practice.Conclusions
Combined laparoscopy and hysteroscopy, which can safely
and thoroughly remove the ectopic conceptus and repair
the scar tissue defect, is more suitable than uterine curet-
tage as a supplementary measure for the UAE-based man-
agement of CSP.
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